Why successful treatment involves more than the number on the scales

How do we support patients using GLP-1 medicines? By looking beyond the number on the scales.

GLP-1 and related medicines can be highly effective tools for weight management and blood-glucose control. By reducing appetite, increasing feelings of fullness and slowing the movement of food through the stomach, they can help people achieve substantial and clinically meaningful weight loss. Tirzepatide acts on both GLP-1 and GIP receptors but is commonly discussed alongside GLP-1 medicines because of its similar effects on appetite, glucose regulation and body weight.

However, successful treatment involves more than losing weight. As appetite, food intake and digestion change, attention must also be paid to nourishment, bowel function, hydration, electrolyte balance, muscle and bone health, sleep, cardiovascular function and the gallbladder. Some patients may also need their diabetes, blood-pressure or other medicines reviewed as their physiology changes.

At Wildberry Clinic, our role is to work alongside the prescribing team. We create an individual plan using nutrition, clinical herbal medicine and adapted physical exercise, with the aim of supporting bowel regularity, adequate nourishment, muscle preservation and long-term digestive and metabolic health.

Digestion: when fullness becomes excessive slowing

One of the ways GLP-1 medicines reduce food intake is by slowing gastric emptying. This helps people remain full for longer, but it can also contribute to:

• nausea
• reflux and indigestion
• abdominal fullness or bloating
• vomiting
• constipation
• reduced tolerance of normal-sized meals

With semaglutide, nausea, diarrhoea, vomiting and constipation are among the most frequently reported adverse effects. In clinical trials, constipation affected approximately 24% of patients receiving semaglutide and lasted longer than many of the other gastrointestinal symptoms, with a reported median duration of 47 days.

Tirzepatide is also associated with nausea, vomiting, diarrhoea, constipation, reflux and delayed gastric emptying. Gastrointestinal symptoms tend to be more common during dose escalation and often lessen with time, but persistent or worsening symptoms should not simply be accepted as an unavoidable part of treatment.

Supporting bowel regularity

Constipation during treatment may be influenced by several factors:

• slower movement through the digestive tract
• smaller food portions
• reduced fluid intake
• lower intake of fibre and dietary fats
• reduced physical activity
• other medicines that slow the bowel

The answer is not always to add large quantities of fibre. In someone with severe bloating, marked early fullness, vomiting or possible delayed stomach emptying, rapidly increasing bulky fibre may make symptoms worse.

Our assessment therefore considers the person’s usual bowel pattern, hydration, food intake, fibre tolerance, activity, current medicines and the presence of pain, reflux or nausea. The plan is adjusted to the individual rather than following a standard “GLP-1 protocol.”

Persistent vomiting, substantial abdominal swelling, severe pain, or an inability to pass stool or wind requires medical assessment.

Gallbladder health during weight loss

Gallstones and gallbladder inflammation are recognised complications during treatment with semaglutide and tirzepatide. The risk appears to be influenced partly by the degree and speed of weight loss, as rapid mobilisation of stored fat can change the composition and movement of bile.

In pooled tirzepatide weight-management trials, acute gallbladder events were positively associated with weight reduction. Gallbladder inflammation occurred more frequently in tirzepatide-treated participants than in those receiving placebo, although the overall event rate remained low.

Supportive care cannot guarantee the prevention of gallstones. Our role is to reduce avoidable physiological strain and recognise concerning symptoms early by considering:

• the speed of weight loss
• whether the person is eating regular, nutritionally adequate meals
• hydration and bowel regularity
• previous gallstones or gallbladder disease
• abdominal symptoms and their timing
• medicines and other risk factors

Symptoms requiring medical review include persistent or severe pain in the upper abdomen—particularly on the right side—pain extending towards the back or shoulder, fever, repeated vomiting, jaundice, pale stools or unusually dark urine.

Clinical herbal medicine must never be used to delay investigation of suspected gallstones, gallbladder inflammation or bile-duct obstruction.

Pancreatic awareness

Acute pancreatitis is an uncommon but recognised adverse effect of GLP-1 and dual GIP/GLP-1 medicines. In January 2026, the UK Medicines and Healthcare products Regulatory Agency strengthened warnings after receiving rare reports of severe, necrotising and fatal pancreatitis.

The principal warning symptom is:

Severe, persistent abdominal pain that may travel through to the back, with or without nausea and vomiting.

This requires urgent medical assessment. Because nausea and abdominal discomfort can also occur as ordinary treatment side effects, persistent or unusually severe pain should not be dismissed as the body simply “adjusting” to the medicine.

Hydration, electrolytes and kidney function

GLP-1 medicines do not usually deplete electrolytes directly in the way that a diuretic might.

The concern is more often indirect. Reduced appetite can lead to reduced drinking, while vomiting or diarrhoea can cause a loss of both fluid and electrolytes. Significant dehydration can, in turn, contribute to dizziness, weakness, low blood pressure and deterioration in kidney function.

The current European product information for tirzepatide specifically advises precautions to avoid both fluid depletion and electrolyte disturbances. The risk deserves particular attention in older patients and in people with kidney disease or medicines that influence fluid balance.

We monitor:

• daily fluid intake
• thirst and dry mouth
• dark urine or reduced urination
• headaches or unusual fatigue
• dizziness, especially when standing
• persistent vomiting or diarrhoea
• kidney function where clinically appropriate
• diuretics, blood-pressure medicines and other relevant prescriptions

Electrolyte drinks are not automatically required for everyone taking a GLP-1 medicine. Where significant fluid loss has occurred, an appropriate oral rehydration preparation may be useful. Patients with kidney disease, heart disease, hypertension or medicines affecting sodium or potassium should seek professional advice before using electrolyte products routinely.

Adequate nourishment in a smaller volume of food

Reduced appetite is part of the intended treatment effect. However, if food intake becomes too low, appetite reduction can become under-nutrition. Patients may begin skipping meals, avoiding food because of nausea, or eating portions too small to supply sufficient:

• protein
• iron
• vitamin B12 and folate
• calcium and vitamin D
• zinc
• essential fatty acids
• total energy
• 
  

Signs such as fatigue, weakness, hair shedding, dry skin, poor recovery, feeling cold or reduced exercise capacity may point towards rapid weight loss or inadequate nutritional intake rather than being isolated cosmetic concerns.

Our nutritional planning focuses on the quality and density of the food that can be tolerated, not merely on reducing calories further. Depending on the person, this may involve smaller meals containing sufficient protein, distributing food across the day and addressing digestive symptoms that are preventing adequate eating.

Muscle preservation—and why it matters

Weight loss does not come entirely from body fat. Some lean tissue can also be lost. In the SURMOUNT-1 body-composition substudy, tirzepatide reduced both fat mass and lean mass. Approximately three-quarters of the weight lost was fat mass and one-quarter was lean mass, although the precise balance varied between participants.

Muscle is not simply about physical appearance. It contributes to:

• glucose disposal and metabolic health
• balance and fall prevention
• mobility and independence
• bone loading
• recovery from illness
• long-term physical resilience
• 
  

For this reason, exercise should not be viewed merely as a way to burn additional calories. An adapted programme may include progressive resistance work, physiotherapy-led strengthening, walking, balance exercises and gradual increases in everyday movement. Adequate protein and energy are needed alongside exercise if the aim is to preserve or rebuild muscle.

Bone health and healthy ageing

Muscle and bone function are closely connected. Loss of muscle strength can reduce mechanical loading on the skeleton, while low protein, calcium or vitamin D intake may further compromise musculoskeletal resilience.

This is particularly important for:

• postmenopausal women
• older adults
• people with osteopenia or osteoporosis
• patients at risk of falls
• anyone losing weight rapidly
• people whose food intake has become very restricted
• 
  

Our adapted exercise planning therefore includes weight-bearing movement, resistance work, balance and fall prevention where appropriate—not weight loss alone.

Sleep and recovery

Sleep may change during treatment, but not always in the same direction. For some patients, nausea, reflux, abdominal fullness, constipation, dehydration or insufficient food intake can disturb sleep or contribute to fatigue. Hypoglycaemia may also affect sleep when GLP-1 medicines are used alongside insulin or sulfonylureas.

For others, sleep may improve as weight decreases—particularly where obesity has contributed to obstructive sleep apnoea. In the SURMOUNT-OSA trials, tirzepatide substantially reduced sleep-apnoea severity in adults with obesity and moderate-to-severe obstructive sleep apnoea. This does not mean that existing CPAP or other treatment should be stopped without specialist review.

We ask about:

• sleep duration and quality
• snoring and pauses in breathing
• morning headaches
• daytime sleepiness
• reflux or nausea disturbing sleep
• caffeine, alcohol and meal timing
• whether fatigue could reflect dehydration, under-eating or deficiency

Possible sleep apnoea requires appropriate medical investigation rather than being managed as ordinary tiredness.

Cardiovascular health: benefits and monitoring

Cardiovascular health is an important part of the GLP-1 story. In the SELECT cardiovascular-outcomes trial, semaglutide 2.4 mg reduced the relative risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 20% in adults with established cardiovascular disease and overweight or obesity who did not have diabetes. This benefit relates to a defined patient population and should not be assumed to apply identically to every GLP-1 medicine or every patient.

Weight loss may also improve blood pressure, glucose regulation and blood lipids. However, some patients can experience dizziness, hypotension or postural hypotension—particularly if food and fluid intake fall or existing antihypertensive treatment becomes too strong for their changing physiology. Small increases in resting heart rate have also been observed with semaglutide and tirzepatide.

We therefore consider:

• blood pressure and postural symptoms
• pulse and palpitations
• hydration
• cardiovascular history
• antihypertensive and diuretic medicines
• cholesterol and blood-glucose changes
• the need for review by the prescribing clinician

Medicines should not be reduced or stopped without the relevant prescriber.

Blood glucose and diabetes medicines

GLP-1 and related medicines can lower blood glucose. The risk of significant hypoglycaemia is generally greater when they are combined with insulin or medicines such as sulfonylureas.

Patients using these combinations may require closer glucose monitoring and a prescriber-led adjustment of medication.

A GLP-1 medicine must not be treated as a substitute for insulin. Insulin should not be rapidly reduced or stopped without specialist medical direction, because this can result in serious loss of glycaemic control.

Oral medicines and delayed stomach emptying

Because these medicines alter gastric emptying, the rate at which some oral medicines are absorbed may change—particularly when treatment begins or the dose is increased.

European product information advises caution with medicines that depend upon rapid absorption or have a narrow therapeutic range. Tirzepatide guidance specifically recommends monitoring medicines such as warfarin and digoxin during initiation and dose escalation.

This does not mean that every oral medicine will become ineffective. It means that the person’s complete medication list should be reviewed rather than assuming that timing and absorption remain unchanged.

For oral HRT or other medicines where consistent exposure is important, concerns should be discussed with the prescriber or pharmacist. There is not currently enough evidence to claim that oral HRT absorption is routinely or significantly impaired in every patient.

Contraception and pregnancy

Pregnancy should be avoided during treatment. Current European product information advises stopping semaglutide at least two months and tirzepatide at least one month before a planned pregnancy.

Advice concerning tirzepatide and oral contraception differs between regulators. European product information states that no dose adjustment is required, while current UK guidance advises additional barrier contraception for four weeks after starting tirzepatide and for four weeks after each dose increase. Patients should follow the advice of their local prescriber, pharmacist and applicable national guidance.

Surgery and anaesthesia

Patients taking a GLP-1 or related medicine should tell the surgical and anaesthetic team before undergoing general anaesthesia or deep sedation.

Because gastric emptying may be delayed, food can remain in the stomach despite ordinary fasting. This may increase the risk of stomach contents entering the airways during a procedure. The anaesthetic team may alter fasting instructions or the anaesthetic approach. Patients should not stop their medicine independently unless instructed by the relevant clinician.

Eye health

Semaglutide requires particular awareness of eye health. Rapid improvement in glucose control can temporarily worsen diabetic retinopathy in some people with diabetes. Current European and UK safety information also identifies a very rare association between semaglutide and non-arteritic anterior ischaemic optic neuropathy, or NAION.

Sudden painless loss of vision or rapidly worsening eyesight requires urgent medical and ophthalmological assessment.

Planning beyond the active weight-loss phase

GLP-1 treatment should not be approached as a short sprint towards a target weight.

In an extension of the STEP 1 trial, participants regained around two-thirds of their previous weight loss during the year after semaglutide was withdrawn, and many cardiometabolic improvements moved back towards baseline.

This does not mean that every patient must remain on the same treatment indefinitely. It does mean that any reduction, discontinuation or maintenance plan should be discussed with the prescribing clinician and accompanied by a longer-term strategy for:

• nutrition
• physical activity and muscle preservation
• sleep
• appetite regulation
• psychological support
• cardiovascular and metabolic monitoring
• follow-up care

How we support patients at Wildberry Clinic

Our approach brings together three connected areas.

Nutrition

We assess food tolerance, meal size, hydration, protein, micronutrients, fibre tolerance and the possible need for electrolyte replacement where fluid loss is present.

Clinical herbal medicine

Where appropriate, an individual prescription may be developed to support digestive comfort, bowel regularity, sleep or wider physiological resilience.

Clinical herbal medicine is not used as a substitute for GLP-1 treatment, emergency assessment or investigation of possible gallbladder, pancreatic or gastrointestinal disease. Each prescription

is built around a full understanding of the patient’s current medication, medical history, digestive motility and potential interactions.

Adapted physical exercise

Movement is planned to preserve muscle, maintain bone loading, improve balance and support cardiovascular and metabolic health. Exercise is adapted to the individual’s strength, symptoms and starting capacity and may be coordinated with physiotherapy where appropriate.

Monitoring and communication

We also monitor how the patient is responding as treatment progresses and encourage appropriate communication with the prescribing clinician. Our aim is not simply a lower number on the scales. It is to help the person remain strong, nourished, well hydrated and physiologically supported throughout treatment.

When urgent medical review is needed

Seek urgent medical advice for:

• severe or persistent abdominal pain, especially if it travels to the back
• pain in the upper-right abdomen with fever or jaundice
• repeated vomiting or inability to retain fluids
• signs of substantial dehydration or markedly reduced urination
• severe abdominal swelling or inability to pass stool or wind
• sudden loss of vision or rapidly worsening eyesight
• severe weakness, fainting or suspected significant hypoglycaemia
• symptoms of a serious allergic reaction

Dose changes and decisions to pause or stop treatment should be made with the prescribing clinician.

🌿 Key Takeaways

• GLP-1 medicines can produce significant metabolic and cardiovascular benefits, but good care must extend beyond weight loss.
• Digestion, bowel motility, gallbladder health, hydration, electrolytes and kidney function may all need attention.
• Adequate nourishment and adapted resistance exercise are important for protecting muscle, bone and physical resilience.
• Sleep may improve with weight loss but can also be disturbed by digestive symptoms, under-nutrition, dehydration or changes in blood glucose.
• Medication absorption, blood pressure, glucose treatment, pregnancy planning, surgery and eye symptoms may require individual review.
• Wildberry Clinic combines nutrition, clinical herbal medicine and adapted physical exercise alongside prescribed medical care.

🌱 A Herbalist’s Perspective

The purpose of integrative care is not to interfere with effective medical treatment. It is to ask what the rest of the body needs while that treatment produces change.

Weight loss affects far more than body size. It can alter appetite, digestion, bile flow, fluid balance, nutritional intake, muscle loading, sleep and medication requirements.

By paying attention to these changes early, we can support the patient as a whole person—not simply measure the outcome on the scales.

Educational and medical disclaimer

This article is provided for educational and informational purposes only. It does not replace medical diagnosis, treatment or consultation with a doctor, prescribing clinician, pharmacist, dietitian, physiotherapist, medical herbalist or another appropriately qualified healthcare professional.

GLP-1 and related medicines must be prescribed, monitored and adjusted by the appropriate prescribing clinician. Do not stop, delay or alter a prescribed dose or another medicine without medical advice. Clinical herbal medicines and supplements may interact with prescribed treatment and require individual assessment. Scientific evidence and medicine-safety guidance continue to evolve.

References and further reading

• European Medicines Agency. Wegovy: European Public Assessment Report and Product Information, updated March 2026.
• European Medicines Agency. Mounjaro: European Public Assessment Report and Product Information, updated February 2026.
• Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes: what you need to know, updated February 2026.
• Medicines and Healthcare products Regulatory Agency. Strengthened warnings on acute pancreatitis, January 2026.
• Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
• Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnoea and obesity. New England Journal of Medicine. 2024.
• Look M, et al. Body-composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes, Obesity and Metabolism. 2025.
• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.